Pharmaceutical Company Achieves Positive In-Vitro Testing Results Diabetes Drug

Thu Jan 31, 2013 9:20am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130131:nPn1302962

Global Pharmaceutical & Biotechnology Outlook for 2013 Continues to be
Encouraging
CORAL SPRINGS, Florida,  January 31, 2013  /PRNewswire/ --

Crown Marketing Pharmaceuticals (OTC:  CWNM) announced today that it has
achieved positive in-vitro testing results of the most widely prescribed
Diabetes drug commonly known as Metformin.   Crown's Controlled Drug Delivery
Device (CDDT) is less than half the size of the 500mg dosage tablet, and may
reduce and ameliorate many of the gastrointestinal side effects of Metformin. 
The most common adverse effects of Metformin are gastrointestinal upset
including diarrhea, cramps, nausea and vomiting.  Crown Marketing
Pharmaceuticals (OTC:  CWNM) believes it can significantly reduce or eliminate
these effects with its patented technology.

Patients also have issues about the taste and odor associated with the
medication.  Common complaints are that it "smells fishy" and can leave a
metallic taste in the mouth.  This is critical because it impacts patient
compliance-if it tastes or smells bad, patients oftentimes will not take the
medication as directed.  Crown's CDDT can overcome these issues due to its
novel, diffusion based design and its impermable coating. According to IMS
figures, the total market sales for all forms of Metformin were  $1.6 billion,
with sales of Metformin extended-release formulation alone accounting for over 
$460 million  last year.

Metformin is an pharmaceutical oral diabetes medicine that helps control blood
sugar levels originally sold as Glucophage.  Metformin is for people with type 2
diabetes. Metformin is sometimes used in combination with insulin or other
medications, but it is not for treating type 1 diabetes.  One of the more common
long-term complications of diabetes is diabetic renal disease ("renal" refers to
the kidneys). Also known as diabetic nephropathy, this condition is a result of
direct vascular abnormalities that accompany diabetes.   Keryx
Biopharmaceuticals Inc. (NASDAQ:  KERX)  announced this week that its kidney
disease drug, Zerenex, is also receiving positive signs as it has performed
better than a placebo in late-stage clinical trials.  The New York company said
Monday that Zerenex showed a "highly statistically significant" change in serum
phosphorus levels compared with a placebo in patients with advanced kidney
failure who were on dialysis.  Keryx Biopharmaceuticals Inc. (NASDAQ:  KERX)
closed up yesterday at  $8.49  per share on large trading volume over
49.1Million shares traded.

The Global Pharmaceutical & Biotechnology sector continues to remain attractive,
as cost containment initiatives, restructuring/deconsolidation, share repurchase
program, M&A, emerging market growth potential and dividend policy continue to
be encouraging. Over the next few years, the growth of the industry would be
shaped up by a battle between fundamental growth drivers (Value added
innovation) versus regulatory pressures to contain costs.  In Merger &
Acquisition news, MAP Pharmaceuticals, Inc. (NASDAQ:  MAPP) is a
biopharmaceutical company focused on developing and commercializing new
therapies to address undermet patient needs in neurology. The Company is
developing LEVADEX, an orally inhaled investigational drug for the acute
treatment of migraine.  Allergan, Inc. (NYSE:  AGN) inked a deal with MAP
Pharmaceuticals, Inc. (NASDAQ:  MAPP) to acquire the latter. As per the terms of
the deal, Allergan will acquire all the shares of MAP Pharmaceuticals for 
$25.00  per share. The offer price represents premium of 60% over MAP
Pharmaceuticals' closing price back on  Jan 22, 2012.

Another leader in the sector, Amarin Corporation (NASDAQ:  AMRN) was originally
a small British drug delivery company, which evolved into a cardiovascular drug
development company and is now among the more promising biopharmaceutical
companies in the US. Vascepa (icosapent ethyl) for treatment of
hypertriglyceridemia is Amarin's first FDA approved product, whose market
introduction was announced by the company on  January 24, 2013.
Hypertriglyceridemia refers to high blood level of triglycerides, a blood fat
that contributes to cardiovascular problems.

FinancialNewsMedia.com  is leading provider of third party publishing & news
dissemination services. If you would like more information regarding our news
coverage solutions, please visit http://www.financialnewsmedia.com    for more
details.

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels.  FNMG is NOT affiliated in any manner
with any company mentioned herein.  FNMG and its affiliated companies are a news
dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security.  FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities.  The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material.   All readers are strongly urged to perform research and due diligence
on their own and consult a licensed financial professional before considering
any level of investing in stocks.  The companies that are discussed in this
release may or may not have approved the statements made in this release.  FNMG
is not liable for any investment decisions by its readers or subscribers. 
Investors are cautioned that they may lose all or a portion of their investment
when investing in stocks.

To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always
disclose any compensation it has received, or expects to receive in the future,
for the dissemination of the information found herein on behalf of one or more
of the companies mentioned in this release.  For disseminating this release,
FNMG was not compensated by any companies mentioned herein this release.  FNMG
HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE AND WAS NOT COMPENSATED BY
ON OTHER COMPANY INCLUDED HEREIN.   

This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and FNMG undertakes no obligation to update such
statements.

Contact Information:

Company:  FN Media Group, LLC

Contact email:  editor@financialnewsmedia.com

U.S. Phone: +1(954)345-0611

URL:  http://www.financialnewsmedia.com


SOURCE  FN Media Group LLC

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.